GENinCode PLC Result of AGM

RNS Number : 2206U

GENinCode PLC

27 June 2024

 

GENinCode Plc

("GENinCode" or the "Company")

 

Result of AGM

 

Oxford, UK. GENinCode Plc (AIM: GENI), the predictive genetics company focused on the prevention of cardiovascular disease and ovarian cancer, announces that at the Annual General Meeting held earlier today, all resolutions were duly passed.

 

A copy of the voting results can be found on the website later today here.

 

For more information visit www.genincode.com

 

Enquiries:

GENinCode Plc	www.genincode.com or via Walbrook PR
Matthew Walls, CEO
Paul Foulger, CFO
Cavendish Capital Markets Limited	Tel: [phone]
Giles Balleny / Dan Hodkinson (Corporate Finance)
Nigel Birks / Harriet Ward (Corporate Broking)
Dale Bellis / Michael Johnson (Sales)
Walbrook PR Limited Anna Dunphy / Louis Ashe-Jepson / Phillip Marriage		Tel: [phone] or [e-mail]

 

 

About GENinCode:

 

GENinCode Plc is a UK based company specialising in genetic risk assessment of cardiovascular disease and ovarian cancer. Cardiovascular disease is the leading cause of death and disability worldwide.

 

GENinCode operates business units in the UK, Europe through GENinCode S.L.U, and in the United States through GENinCode U.S. Inc.

 

GENinCode predictive technology provides patients and physicians with globally leading preventive care and treatment strategies. GENinCode invitro-diagnostic molecular tests combine clinical algorithms and AI bioinformatics to advance patient risk assessment to prevent the onset of cardiovascular disease and ovarian cancer.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

RAGBSGDLRUDDGSR